CS Medica (NGM:CSMED) - Stock Price, News & Analysis

CSMED Stock Overview

CS MEDICA A/S desarrolla, fabrica y comercializa productos médicos de venta libre que contienen cannabinoides para el tratamiento de la psoriasis y la artritis.

About the company

CSMED fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Los beneficios han disminuido en 67.1% al año en los últimos 5 años.

Tiene menos de 1 año de cash runway

Cotización muy volátil en los últimos 3 meses

Tiene unos ingresos inferiores a 1 millón de dólares (DKK1M)

+ 1 more risk

CS Medica A/S Competitors

AcuCort

NGM:ACUC

kr62.6m

Emplicure

OM:EMPLI

kr46.5m

PEPTONIC medical

NGM:PMED

kr92.1m

ODI Pharma

NGM:ODI

kr78.4m

Price History & Performance

Summary of all time highs, changes and price drops for CS Medica
Historical stock prices
Current Share Price	kr.5.97
52 Week High	kr.11.33
52 Week Low	kr.3.05
Beta	-1.62
1 Month Change	1.81%
3 Month Change	-15.97%
1 Year Change	-38.54%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-43.99%

Recent updates

Shareholder Returns

	CSMED	SE Pharmaceuticals	SE Market
7D	-15.5%	2.6%	0.06%
1Y	-38.5%	71.3%	14.0%

Rentabilidad frente al sector: CSMED obtuvo unos resultados inferiores a los del sector Swedish Pharmaceuticals , que el año pasado arrojó un rendimiento del 67.4%.

Rentabilidad vs. Mercado: CSMED obtuvo unos resultados inferiores a los del mercado Swedish, que fue del 15% el año pasado.

Price Volatility

Is CSMED's price volatile compared to industry and market?
CSMED volatility
CSMED Average Weekly Movement	18.2%
Pharmaceuticals Industry Average Movement	7.4%
Market Average Movement	6.1%
10% most volatile stocks in SE Market	13.3%
10% least volatile stocks in SE Market	3.5%

Precio estable de las acciones: CSMEDha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: CSMED(19%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de Swedish.

About the Company

Founded	Employees	CEO	Website
2011	9	Lone Henriksen	https://www.cs-medica.com

CS MEDICA A/S desarrolla, fabrica y comercializa productos médicos de venta libre que contienen cannabinoides para el tratamiento de la psoriasis y la artritis. Ofrece geles para la psoriasis, la artritis, la protección nasal y la cicatrización de heridas; y suero CBD contra la caída del cabello, así como aerosoles nasales para dormir y parches para el dolor. La empresa ofrece principalmente sus productos bajo la marca CANNASEN.

CS Medica A/S Fundamentals Summary

How do CS Medica's earnings and revenue compare to its market cap?
CSMED fundamental statistics
Market cap	kr.47.81m
Earnings (TTM)	-kr.14.51m
Revenue (TTM)	kr.1.07m

68.9x

P/S Ratio

-5.1x

P/E Ratio

Is CSMED overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSMED income statement (TTM)
Revenue	kr.1.07m
Cost of Revenue	kr.153.73k
Gross Profit	kr.913.55k
Other Expenses	kr.15.43m
Earnings	-kr.14.51m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 12, 2024

Earnings per share (EPS)	-1.18
Gross Margin	85.60%
Net Profit Margin	-1,359.80%
Debt/Equity Ratio	84.3%

How did CSMED perform over the long term?

See historical performance and comparison

CSMED Stock Overview

Rewards

Risk Analysis

CS Medica A/S Competitors

NGM:ACUC

kr62.6m

OM:EMPLI

kr46.5m

NGM:PMED

kr92.1m

NGM:ODI

kr78.4m

Price History & Performance

Recent News & Updates

CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

CS Medica A/S to Report 3 Months Period Ending Dec 31, 2023 Results on Mar 29, 2024

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report 3 Months 2023 Final Results on Apr 24, 2024

CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

Recent updates

CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

CS Medica A/S to Report 3 Months Period Ending Dec 31, 2023 Results on Mar 29, 2024

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report 3 Months 2023 Final Results on Apr 24, 2024

CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report Q4, 2024 Results on Nov 14, 2024

Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products

New major risk - Share price stability

New major risk - Market cap size

CS Medica A/S to Report Q3, 2023 Results on Aug 08, 2023

CS Medica A/S to Report Q3, 2023 Results on Jul 18, 2023

CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body

New major risk - Market cap size

CS Medica A/S Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis

CS Medica A/S to Report Fiscal Year 2022 Final Results on Jan 27, 2023

CS Medica A/S to Report Q1, 2023 Results on Feb 17, 2023

CS Medica A/S, Annual General Meeting, Feb 09, 2023

CS Medica A/S Provides Update on Clinical Trials

Full year 2022 earnings released: kr.0.90 loss per share (vs kr.0.059 profit in FY 2021)

No independent directors

CS Medica A/S and CanNordic A/S Announce the Resignation of Bo Unéus as Board Member

CS Medica A/S Provides Revenue Guidance for the Year 2022

CS MEDICA Provides Patent Update

CS Medica A/S to Report Fiscal Year 2022 Results on Nov 18, 2022

CS MEDICA A/S Reports Proof of Concept in the Results from the Clinical Trial on NGP-01 (Cannasen®Cbd Psoriasis Gel) Against Placebo

CS MEDICA A/S Announces Groundbreaking Discovery in the Natural Cannabinoid CBD's Activity in the Body

Cs Medica Announces Positive Clinical Trial Results from the Final Report on Nga-01 Gel & Nsa-01 Capsule in Combination Against Placebo

CS Medica A/S Reports the Results from the Clinical Trial on NGA-01(CANNASEN®CBD Arthritis Gel) Against Placebo

CS MEDICA A/S Provides Revenue Guidance for 2023/2024

No independent directors

CS Medica Receives the Final Approval from Hong Kong Customs, the Drug Registration Office

CS MEDICA A/S Provides Patent Update

CS MEDICA A/S Finalizes THC Test At PPB Level on Their Cannasen®Cbd Products to Comply with the Strict Regulations on the Asian Market

CS MEDICA A/S Appoints Heidi Ahlefeldt-Laurvig as Chief Growth Officer and Chief Marketing Officer, Effective May 1, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CS MEDICA A/S Reaffirms Revenue Guidance for the Fiscal Year 2022

CS MEDICA A/S Announces Their CANNANSEN®CBD Anti-Hair Loss Serum Approves in the United Arab Emirates

CS MEDICA A/S Announces an Additional Five Intellectual Property Rights Registrations

No independent directors

Shareholder Returns

Price Volatility

About the Company

CS Medica A/S Fundamentals Summary

68.9x

-5.1x

Earnings & Revenue